Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Upper and Lower Limb Spasticity
NCT01603459Phase 3Completed
- Sponsor
- Merz
- Start
- May 2012
- Primary completion
- Sep 2014
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of incobotulinumtoxinA in spasticity, sponsored by Merz. Primary endpoints: Treatment-Emergent Adverse Events at 48 weeks and Investigator's Global Assessment of Tolerability at 48 weeks. Started May 2012; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT01603459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01603459.